Literature DB >> 22884602

Outcomes of mechanical valves in the pulmonic position in patients with congenital heart disease over a 20-year period.

Hong Ju Shin1, Young-Hwue Kim, Jae-Kon Ko, In-Sook Park, Dong Man Seo.   

Abstract

BACKGROUND: Homografts or bioprosthetic valves have been preferred in the pulmonic position in patients with congenital heart disease. However, unsatisfactory long-term results have aroused interest in the use of mechanical valves. In this study, we investigated the long-term outcomes of mechanical valves implanted in the pulmonic position.
METHODS: The medical records of 37 patients (27 male, 73%) who underwent 38 mechanical pulmonary valve replacements between October 1988 and February 2011 were reviewed, retrospectively. The median age of patients was 13.5 years (range, 7 months to 23 years), and the median number of prior operations per patient was 2 (range, 0 to 5). Tetralogy of Fallot was the most common diagnosis (n=23). The median valve size was 23 mm (range, 17 to 27 mm), and the median follow-up duration after pulmonary valve replacement was 24.6 months (range, 1.3 months to 22.5 years). Events were defined as the following: valve failure, thrombosis, embolism, bleeding, reoperation, and death.
RESULTS: There was no in-hospital mortality, but there were 2 late deaths (1 heart failure and 1 traffic accident at 10.8 months and 8.7 years postoperatively, respectively). Excluding the traffic accident death, survival rates were 97%, 97%, and 97%, at 1, 5, and 10 years, respectively. Freedom from thromboembolism or bleeding events was 92%, 92%, and 78.8%, at 1, 5 and 10 years, respectively. Two reoperations were performed at 6.8 and 10.2 years postoperatively. Freedom from reoperation was 100%, 100%, and 85.7%, at 1, 5, and 10 years, respectively.
CONCLUSIONS: Durability of mechanical valve in pulmonic position was excellent. Thromboembolism or bleeding events due to anticoagulation therapy were rare. In growing patients who have undergone prior sternotomies requiring a pulmonary valve replacement, a mechanical valve could be an attractive option.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22884602     DOI: 10.1016/j.athoracsur.2012.07.008

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Quadruple valve replacement for rheumatic valvular disease. Excellent durability for 20 years.

Authors:  A B Budak; K Korkmaz; H S Gedik; S B Genç; A Ü Yener; İ Alur; K Çağlı
Journal:  Herz       Date:  2014-04-11       Impact factor: 1.443

Review 2.  Postoperative residua and sequelae in adults with repaired tetralogy of Fallot.

Authors:  Munetaka Masuda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-04-26

Review 3.  Current status of right ventricular outflow tract reconstruction: complete translation of a review article originally published in Kyobu Geka 2014;67:65-77.

Authors:  Yusuke Yamamoto; Masaaki Yamagishi; Takako Miyazaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-12-13

4.  Mid-term outcomes of mechanical pulmonary valve replacement: a single-institutional experience of 396 patients.

Authors:  Maziar Gholampour Dehaki; Alwaleed Al-Dairy; Yousef Rezaei; Gholamreza Omrani; Amir Hossein Jalali; Hoda Javadikasgari; Mahyar Gholampour Dehaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-09-12

Review 5.  Recent Development in Pulmonary Valve Replacement after Tetralogy of Fallot Repair: The Emergence of Hybrid Approaches.

Authors:  Tariq Suleiman; Clifford J Kavinsky; Clare Skerritt; Damien Kenny; Michael N Ilbawi; Massimo Caputo
Journal:  Front Surg       Date:  2015-06-02

Review 6.  Clinical performance of decellularized heart valves versus standard tissue conduits: a systematic review and meta-analysis.

Authors:  Steve W F R Waqanivavalagi; Sameer Bhat; Marcus B Ground; Paget F Milsom; Jillian Cornish
Journal:  J Cardiothorac Surg       Date:  2020-09-18       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.